TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06613698: A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)

Sponsor: GlaxoSmithKline · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 393 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT06613698 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06613698 Rescue Dossier →